IDEXX Laboratories director Karen Peacock reported a routine equity compensation event. On May 7, 2026, she exercised 101 Restricted Stock Units, receiving 101 shares of common stock at an exercise price of $0.00 per share. Following this vesting and conversion, she directly holds 102 shares of common stock. No shares were sold and no tax-withholding dispositions were reported in this filing.
IDEXX Laboratories director Lawrence D. Kingsley reported the vesting and exercise of restricted stock units into common shares. On May 7, 2026, 82 and 257 restricted stock units each converted into the same number of IDEXX common shares at a stated price of $0.00 per share.
Each restricted stock unit represented a right to receive one share of common stock that vested in a single installment on May 7, 2026. The filing shows only derivative exercises and conversions, with no open-market purchases or sales. These transactions reflect compensation-related equity vesting rather than discretionary trading.
Director Daniel M. Junius of IDEXX Laboratories reported a routine equity compensation event. On May 7, 2026, a grant of 257 restricted stock units vested, converting into 257 shares of common stock. After this vesting and conversion, he directly holds 3,561 shares of IDEXX common stock.
IDEXX Laboratories director Joseph L. Hooley reported a routine equity compensation event. On May 7, 2026, 158 restricted stock units vested and were converted into 158 shares of IDEXX common stock, with no sale involved.
Following this exercise and conversion of the derivative security, Hooley directly holds 276 shares of common stock. The vested RSUs represented a contingent right to receive one share of common stock per unit, vesting in a single installment on May 7, 2026.
IDEXX Laboratories reported solid growth for the quarter ended March 31, 2026. Total revenue rose to $1.14 billion from $998.4 million a year earlier, driven mainly by higher Companion Animal Group diagnostic and software revenues and broader international demand.
Net income increased to $278.4 million from $242.7 million, with diluted earnings per share up to $3.47 from $2.96. Operating cash flow was strong at $266.2 million, supporting continued investment and capital returns, including $360.8 million of open-market share repurchases and ongoing use of the company’s credit facility and senior notes.
IDEXX Laboratories reported strong first quarter 2026 results, with revenue of $1.14 billion, up 14% as reported and 11% organically. Growth was led by Companion Animal Group revenue, including 14% reported and 11% organic CAG Diagnostics recurring revenue growth, and 33% reported growth in diagnostics capital instruments.
Diluted EPS was $3.47, up 17% as reported and 15% on a comparable basis. Gross margin improved to 63.4% and operating margin to 31.8%. Free cash flow was $234 million. Management raised full-year 2026 guidance, targeting revenue of $4.675–$4.760 billion, organic growth of 7.7%–9.7%, and EPS of $14.45–$14.90.
IDEXX Laboratories director Joseph L. Hooley acquired 43 deferred stock units tied to the company’s common stock as a compensation award. The units were valued using a reference price of $560.80 per share, reflecting the conversion of $24,375.00 of cash compensation he chose to defer.
Each deferred stock unit represents the right to receive one IDEXX share in the future. The units vest immediately and will be settled in stock after Hooley leaves the Board or on another fixed date allowed under the director plan. Following this grant, he directly holds 118 deferred stock units.
IDEXX Laboratories Inc reported that Vanguard Capital Management beneficially owns 5,976,472 shares of Common Stock, representing 7.51% of the class. The filer reports sole dispositive power over 5,976,472 shares and sole voting power over 793,965 shares. The filing states the ownership reflects securities held by Vanguard affiliates and funds and is signed by Ashley Grim, Head of Global Fund Administration.
IDEXX Laboratories presents its 2026 proxy, highlighting strong 2025 growth, major product launches, an upcoming CEO transition and several governance proposals. Revenue reached $4.3B, up 10%, with operating profit of $1.4B and diluted EPS of $13.08, a 23% increase, supported by margin expansion and resilient demand despite lower U.S. vet visit volumes.
The company underscores innovation such as IDEXX Cancer Dx for early canine cancer detection, the inVue Dx cellular analyzer and the ImageVue DR50 Plus imaging system. Shareholders will vote on director elections, auditor ratification, executive pay, declassifying the Board, a 25% special-meeting right and a separate special-meeting shareholder proposal the Board opposes.